Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

China flag China · Delayed Price · Currency is CNY
30.18
+0.83 (2.83%)
Jan 5, 2026, 3:04 PM CST
-0.46%
Market Cap46.69B
Revenue (ttm)18.30B
Net Income (ttm)1.67B
Shares Out1.59B
EPS (ttm)1.04
PE Ratio28.17
Forward PE23.59
Dividend0.76 (2.60%)
Ex-Dividend DateOct 21, 2025
Volume26,452,152
Average Volume13,425,969
Open29.40
Previous Close29.35
Day's Range28.71 - 30.60
52-Week Range26.72 - 41.72
Beta-0.03
RSI31.88
Earnings DateApr 3, 2026

About SHE:002422

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-em... [Read more]

Sector Healthcare
Founded 1996
Employees 21,864
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002422
Full Company Profile

Financial Performance

In 2024, SHE:002422's revenue was 21.81 billion, an increase of 1.67% compared to the previous year's 21.45 billion. Earnings were 2.94 billion, an increase of 19.53%.

Financial Statements

News

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

4 weeks ago - Nasdaq